Apogee Therapeutics, Inc. Common Stock(APGE)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

APGE $135.08
Snapshot
$135.08
52-Week Range
$35.39 – $135.09
YTD
+78.25%
IV Rank (30D)
24.98
Straddle Price
$5.12
P/C Vol Ratio
0.30
Market Cap
$10.2B
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.67%
Beta vs SPY1.00
Cost of Equity (CAPM)10.17% (VRP-adj)
WACC10.16%
Volatility Risk Premium+43.1pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.2B
Return on Equity (TTM)-24.6%
Book / Price13.0%
Debt / Equity0.00
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$134.03 (Market Anchor value)
SMA 20 / Bollinger Mid$134.68
Bollinger Width / SMA200.5% (drives anchor stability)
Net Debt$-0.1B
Market Cap$9B
Peers used for multiples: ABBV, ABT, BSX, ISRG, JNJ, KYMR, LLY, MRK
Model Conviction
96%
20-Day Fair Value
≈ by Sep 30, 2026
$142.15
α +5.2% rank 49%
40-Day Fair Value
≈ by Oct 29, 2026
$144.22
α +6.8% rank 23%
60-Day Fair Value
≈ by Nov 27, 2026
$156.13
α +15.6% rank 30%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 39.2× · 7 peers
Peer EV/EBITDA n/a 0% median 20.6× · 7 peers
Peer P/B $127.72 16% median 7.2× · 7 peers
Peer P/S n/a 0% median 6.8× · 8 peers
Market Anchor (SMA50) $134.03 84% stability 100% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-09-01 · updated
Info
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836)
Exchange
XNAS
Market Cap
$10.2B

Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other p…

Summary
composite
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
MonthAvg ReturnYears of Data
Jan -0.24% 3
Feb -5.83% 3
Mar +45.27% 3
Apr -2.30% 3
May -5.97% 3
Jun +24.91% 3
Jul +5.55% 4
Aug +1.55% 4
Sep +5.93% 4
Oct +4.13% 3
Nov +7.14% 3
Dec +18.65% 3
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $134.72
SMA 50: $134.08
SMA 200: $91.61
Current: $135.08
EMA 12: $134.85
EMA 26: $133.65
MACD: 1.1986 | Signal: -0.4185
BULLISH
ADX (14): 65.33
STRONG TREND
+DI: 44.89
−DI: 8.54

Momentum Oscillators

RSI (14): 78.95
OVERBOUGHT
Stoch %K: 98.39
Stoch %D: 96.83
Williams %R: -1.45

Volume & Volatility

BB Upper: $135.16
BB Lower: $134.29
NEUTRAL
OBV: 85,957,746
Vol SMA 20: 1,234,938
Vol ROC: 8.58%
ATR: $0.35
True Range: $0.08
HV 20: 1.4%
HV 30: 1.4%
HV 60: 81.6%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-09-04T00:00:00 – 2026-09-01T00:00:00
AI Analysis

Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

News
Earnings History
6 of 7 under expected move
Avg Expected Move
9.11%
Avg Actual Move
3.83%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-11-12 After-Close 11.33% 7.95% 0.70x Within
2025-03-03 After-Close 13.62% 3.25% 0.24x Within
2025-05-12 After-Close 13.75% 0.65% 0.05x Within
2025-08-11 Pre-Market 9.25% 2.09% 0.23x Within
2025-11-10 After-Close 9.56% 10.89% 1.14x Exceeded
2026-05-11 After-Close 5.97% 1.97% 0.33x Within
2026-08-10 After-Close 0.30% 0.03% 0.10x Within
Options Activity
IV Rank (30D)
24.98
IV Rank (7D)
24.98
Avg IV
46.4%
Straddle (30D)
$5.12
Straddle (7D)
$5.12
P/C Volume
0.30
Spread Scanner GPU

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
pts EXTREME
ATM — / Wing —
30 DTE / 10d
pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
0.92
Correlation (SPY)
16.9%
0.03
Ann. Volatility
69.6%
SPY Volatility
12.8%

Moderate volatility - stock generally follows market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-06-30
Diluted shares outstanding: 67,812,899 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

293 filers69,554,445 shares$8.52B value102.57% of float
# Filer Shares Value % of Total % of Float Period
1 Venrock Adviser, LLC 8,493,321 $1.13B 13.24% 12.52% 2026-06-30
2 BlackRock, Inc. Custodian 5,507,032 $730.95M 8.58% 8.12% 2026-06-30
3 VANGUARD CAPITAL MANAGEMENT LLC 2,572,119 $341.40M 4.01% 3.79% 2026-06-30
4 FMR LLC Custodian 2,493,137 $330.91M 3.89% 3.68% 2026-06-30
5 STATE STREET CORP 2,297,743 $304.98M 3.58% 3.39% 2026-06-30
6 DRIEHAUS CAPITAL MANAGEMENT LLC 1,740,101 $230.96M 2.71% 2.57% 2026-06-30
7 GOLDMAN SACHS GROUP INC Custodian 1,693,341 $224.76M 2.64% 2.50% 2026-06-30
8 BALYASNY ASSET MANAGEMENT L.P. 1,665,102 $221.01M 2.59% 2.46% 2026-06-30
9 VANGUARD GROUP INC Custodian 2,857,824 $215.71M 2.53% 4.21% 2025-12-31
10 Paradigm Biocapital Advisors LP 1,576,385 $209.23M 2.46% 2.32% 2026-06-30
11 VANGUARD PORTFOLIO MANAGEMENT LLC 1,528,750 $202.91M 2.38% 2.25% 2026-06-30
12 JANUS HENDERSON GROUP PLC 2,360,596 $198.81M 2.33% 3.48% 2026-03-31
13 MILLENNIUM MANAGEMENT LLC Custodian 1,491,404 $197.95M 2.32% 2.20% 2026-06-30
14 Pentwater Capital Management LP 1,425,000 $189.14M 2.22% 2.10% 2026-06-30
15 MORGAN STANLEY Custodian 1,421,681 $188.70M 2.22% 2.10% 2026-06-30
16 GEODE CAPITAL MANAGEMENT, LLC Custodian 1,314,868 $174.56M 2.05% 1.94% 2026-06-30
17 PERCEPTIVE ADVISORS LLC 1,308,113 $173.63M 2.04% 1.93% 2026-06-30
18 Jupiter Topco LLC 1,193,626 $158.40M 1.86% 1.76% 2026-06-30
19 BANK OF AMERICA CORP /DE/ Custodian 1,126,139 $149.47M 1.75% 1.66% 2026-06-30
20 Affinity Asset Advisors, LLC 987,000 $131.00M 1.54% 1.46% 2026-06-30
21 MERCER GLOBAL ADVISORS INC /ADV 941,283 $124.94M 1.47% 1.39% 2026-06-30
22 First Light Asset Management, LLC 930,289 $123.48M 1.45% 1.37% 2026-06-30
23 Kryger Capital LLC 742,555 $98.56M 1.16% 1.09% 2026-06-30
24 Qube Research & Technologies Ltd 659,678 $87.56M 1.03% 0.97% 2026-06-30
25 First Trust Capital Management L.P. 625,182 $82.98M 0.97% 0.92% 2026-06-30
11 filers$37.27M notional
# Filer Notional Value % of Total Period
1 ExodusPoint Capital Management, LP $11.61M 31.15% 2026-06-30
2 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $9.77M 26.21% 2026-06-30
3 Symmetry Investments LP $6.64M 17.81% 2026-06-30
4 JANE STREET GROUP, LLC Custodian $3.56M 9.55% 2026-06-30
5 SIMPLEX TRADING, LLC Custodian $1.42M 3.81% 2026-06-30
6 MILLENNIUM MANAGEMENT LLC Custodian $1.34M 3.60% 2026-06-30
7 Twin Tree Management, LP $1.06M 2.85% 2026-06-30
8 CITADEL ADVISORS LLC Custodian $929.11K 2.49% 2026-06-30
9 Schonfeld Strategic Advisors LLC $663.65K 1.78% 2026-06-30
10 Verition Fund Management LLC $265.46K 0.71% 2026-06-30
11 GROUP ONE TRADING LLC Custodian $13.27K 0.04% 2026-06-30
15 filers$162.14M notional
# Filer Notional Value % of Total Period
1 BALYASNY ASSET MANAGEMENT L.P. $66.36M 40.93% 2026-06-30
2 SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian $26.92M 16.60% 2026-06-30
3 PICTON MAHONEY ASSET MANAGEMENT $26.55M 16.37% 2026-06-30
4 Caption Management, LLC $15.36M 9.47% 2026-06-30
5 TUDOR INVESTMENT CORP ET AL $13.35M 8.24% 2026-06-30
6 JANE STREET GROUP, LLC Custodian $3.92M 2.41% 2026-06-30
7 SIMPLEX TRADING, LLC Custodian $3.12M 1.92% 2026-06-30
8 WATER ISLAND CAPITAL LLC $2.32M 1.43% 2026-06-30
9 JPMORGAN CHASE & CO Custodian $1.98M 1.22% 2026-06-30
10 CITADEL ADVISORS LLC Custodian $1.06M 0.65% 2026-06-30
11 Twin Tree Management, LP $623.83K 0.38% 2026-06-30
12 Walleye Trading LLC $358.37K 0.22% 2026-06-30
13 GROUP ONE TRADING LLC Custodian $132.73K 0.08% 2026-06-30
14 WOLVERINE ASSET MANAGEMENT LLC $66.36K 0.04% 2026-06-30
15 Polar Asset Management Partners Inc. $26.55K 0.02% 2026-06-30
Insider Activity
Latest: 2026-08-11
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-08-11 Tomas Kiselak Director Exer (M) +168,832 $23.60 $3.98M EDGAR
2026-08-07 Carl Dambkowski Chief Medical Officer Mixed −1,375 $86.47 -$643.6K EDGAR
2026-08-07 Carl Dambkowski Chief Medical Officer Mixed −1,375 $86.47 -$643.6K EDGAR
2026-07-24 Jane Henderson Chief Financial Officer Gift (G) −15,000 EDGAR
2026-07-16 Carl Dambkowski Chief Medical Officer Gift (G) −8,000 EDGAR
2026-07-10 MICHAEL THOMAS HENDERSON Chief Executive Officer Mixed −95,046 $133.63 -$2.67M EDGAR
2026-07-02 Carl Dambkowski Chief Medical Officer Mixed −1,375 $85.65 -$635.8K EDGAR
2026-06-24 Carl Dambkowski Chief Medical Officer Sell (S) −26,400 $132.60 -$3.50M EDGAR
2026-06-24 MICHAEL THOMAS HENDERSON Chief Executive Officer Sell (S) −80,000 $132.54 -$10.60M EDGAR
2026-06-12 MICHAEL THOMAS HENDERSON Chief Executive Officer Sell (S) −20,000 $83.38 -$1.67M EDGAR
2026-06-11 Lisa Bollinger Director Grant (A) +7,657 opt EDGAR
2026-06-11 Tomas Kiselak Director Grant (A) +15,314 opt EDGAR
2026-06-11 Mark C. McKenna Director Grant (A) +7,657 opt EDGAR
2026-06-11 Nimish P Shah Director Grant (A) +7,657 opt EDGAR
2026-06-11 Jennifer A. Fox Director Grant (A) +7,657 opt EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
6 insiders · @ $135.08
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Nimish P Shah Director 1,750,000 $236.39M $29.75M 5 2026-06-11
2 MICHAEL THOMAS HENDERSON Chief Executive Officer 920,941 $124.40M -$37.96M 25 2026-07-10
3 Carl Dambkowski Chief Medical Officer 168,498 $22.76M -$14.41M 33 2026-08-07
4 Jane Henderson Chief Financial Officer 158,371 $21.39M -$2.38M 16 2026-07-24
5 Tomas Kiselak Director 51,166 $6.91M -$534.10M 4 2026-08-11
6 Mark C. McKenna Director 20,000 $2.70M $990.8K 5 2026-06-11
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
Notice of Proposed Sale (Form 144)
Latest: 2026-07-01
Last 30d: 0 filings  ·  Last 90d: 3 filings · $14.2M notice value · 2 unique filers · 100% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: HENDERSON MICHAEL THOMAS (1, $10.6M) · CARL DAMBKOWSKI (2, $3.6M)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-07-01 CARL DAMBKOWSKI Officer 16,500 $2.19M 2026-07-01 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-06-22 CARL DAMBKOWSKI Officer 15,400 $1.39M 2026-06-22 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-06-22 HENDERSON MICHAEL THOMAS Officer, Director 80,000 $10.60M 2026-06-22 THE CHARLES SCHWAB CORPORATION 10b5-1 EDGAR
2026-05-13 HENDERSON MICHAEL THOMAS Officer, Director 60,000 $4.95M 2026-05-13 THE CHARLES SCHWAB CORPORATION 10b5-1 EDGAR
2026-05-06 CARL DAMBKOWSKI Officer 22,000 $1.83M 2026-05-06 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-05-01 JANE HENDERSON Officer 2,000 $165.8K 2026-05-01 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-03-25 JANE HENDERSON Officer 6,000 $438.0K 2026-03-25 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-02-11 HENDERSON MICHAEL THOMAS Officer, Director 60,000 $3.84M 2026-02-11 THE CHARLES SCHWAB CORPORATION 10b5-1 EDGAR
2026-01-22 Fairmount Healthcare Fund II L.P. Director 1,750,000 $133.53M 2026-01-22 Jefferies LLC EDGAR
2026-01-07 CARL DAMBKOWSKI Officer 35,200 $2.75M 2026-01-07 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/B Ratio8.6
EV/EBITDA-31.4
TTM Net Income$-0.3B
TTM EPS$-4.34
ROE-24.6%